scholarly journals Therapeutic strategies for synchronous and multiple liver metastases from colorectal cancer

2012 ◽  
Vol 6 (1) ◽  
pp. 9 ◽  
Author(s):  
Shinji Osada ◽  
Hisashi Imai ◽  
Yoshiyuki Sasaki ◽  
Yoshihiro Tanaka ◽  
Nobuhisa Matsuhashi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastasis ◽  
Therapeutic Strategies ◽  
Optimal Timing ◽  
Critical Factors ◽  
Synchronous Liver Metastasis ◽  
Surgical Strategies ◽  
The Past ◽  
Synchronous Metastases ◽  
Multiple Liver Metastases

Metastasis in the liver is one of the most critical factors in the prognosis of patients with colorectal cancer. The incidence of synchronous liver metastasis has been found to be approximately 20-25%, but the optimal timing of surgical resection remains controversial. Neoadjuvant chemotherapy has also been found to be beneficial not only for initially unresectable but also resectable synchronous metastases and traditional surgical strategies of hepatic resection with past chemotherapeutic regimens have been used less and less over the past several years. This review will discuss treatments in association with the recently developed chemotherapeutic regimens.

scholarly journals Therapeutic strategies for synchronous and multiple liver metastases from colorectal cancer

2012 ◽  
pp. e9
Author(s):  
Shinji Osada ◽  
Hisashi Imai ◽  
Yoshiyuki Sasaki ◽  
Yoshihiro Tanaka ◽  
Nobuhisa Matsuhashi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastasis ◽  
Therapeutic Strategies ◽  
Optimal Timing ◽  
Critical Factors ◽  
Synchronous Liver Metastasis ◽  
Surgical Strategies ◽  
The Past ◽  
Synchronous Metastases ◽  
Multiple Liver Metastases

Metastasis in the liver is one of the most critical factors in the prognosis of patients with colorectal cancer. The incidence of synchronous liver metastasis has been found to be approximately 20-25%, but the optimal timing of surgical resection remains controversial. Neoadjuvant chemotherapy has also been found to be beneficial not only for initially unresectable but also resectable synchronous metastases and traditional surgical strategies of hepatic resection with past chemotherapeutic regimens have been used less and less over the past several years. This review will discuss treatments in association with the recently developed chemotherapeutic regimens.

455. Surgical strategies and outcomes in patients with initially unresectable synchronous liver metastasis from colorectal cancer

2016 ◽  
Vol 42 (9) ◽  
pp. S167
Author(s):  
L. Carrion Alvarez ◽  
F. Pereira Perez ◽  
J.A. Martínez-Piñeiro Muñoz ◽  
A. Antequera Perez ◽  
C. Rihuete Caro ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastasis ◽  
Synchronous Liver Metastasis ◽  
Surgical Strategies

scholarly journals CircRNA circ_0124554 blocked the ubiquitination of AKT promoting the skip lymphovascular invasion on hepatic metastasis in colorectal cancer

2020 ◽  
Author(s):  
Junwei Tang ◽  
Yifei Feng ◽  
Yuanjian Huang ◽  
Ziwei Xu ◽  
Dongsheng Zhang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Lymph Node ◽  
Liver Metastasis ◽  
Hepatic Metastasis ◽  
Vascular Invasion ◽  
Synchronous Liver Metastasis ◽  
Node Negative ◽  
Common Cancer ◽  
Tumor Tissues ◽  
Colorectal Cancer Patients

Abstract Background Colorectal cancer (CRC) is the fourth most common cancer in men and the third most common cancer in women worldwide. The incidence and mortality of CRC was increasing rapidly in China. Lymph node-negative colorectal cancer patients with synchronous liver metastasis (LNLM1) was defined as “skip” lymph vascular invasion on hepatic metastasis, who presenting poor prognosis. We aiming to investigate the potential mechanism for the “skip” lymph vascular invasion on hepatic metastasis in colorectal cancer. Methods The microarray was applied for screening the transcription landscape of circRNA in lymph node negative CRC patients with synchronous liver metastasis (LNLM1) or without liver metastasis (LNLM0). The gain- and loss-of-function experiments was conducted in CRC cell lines and animal models. The RNA pull-down, RNA immunoprecipitation n was further employed in exploring the detailed mechanism of circRNA and associated target genes. Results We identified the aberrant increased circRNA circ_0124554 (also entitled as circ-LNLM) in tumor tissues of LNLM1 patients comparing with either the tumor tissues of LNLM0 or adjacent tissues of LNLM1. Circ-LNLM1 expression was highly corrected with liver metastasis and vascular invasion. Ectopic expression of cytoplasmic located circ-LNLM could promote invasion of CRC cells and induced the liver metastasis in animal models through the direct binding with AKT. The phosphorylation of AKT (T308/S473) was activated due to the blocked ubiquitination site of Lys in 0-52aa peptide of circ-LNLM. Endogenous plasma expression of circ-LNLM induced poor prognosis of LNLM1 and could distinguish LNLM1 patients from LNLM0. Conclusions The circ-LNLM blocked the ubiquitination of AKT could promote the early metastasis especially for the lymph node-negative colorectal cancer patients with synchronous liver metastasis. The circ-LNLM might be prognosis and diagnosis biomarker for LNLM1 patients.

2073 Results of surgical treatment of patients with colorectal cancer and synchronous liver metastasis

2015 ◽  
Vol 51 ◽  
pp. S353
Author(s):  
A. Burlaka ◽  
O. Kolesnik ◽  
A. Lukashenko ◽  
V. Priymak ◽  
I. Shchepotin
Keyword(s):  
Colorectal Cancer ◽  
Surgical Treatment ◽  
Liver Metastasis ◽  
Synchronous Liver Metastasis

scholarly journals Molecular Targets for the Treatment of Metastatic Colorectal Cancer

Cancers ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 2350
Author(s):  
Romain Cohen ◽  
Thomas Pudlarz ◽  
Jean-François Delattre ◽  
Raphaël Colle ◽  
Thierry André
Keyword(s):  
Colorectal Cancer ◽  
Molecular Targets ◽  
Predictive Biomarkers ◽  
Therapeutic Strategies ◽  
Her2 Amplification ◽  
Liquid Biopsies ◽  
Braf Mutations ◽  
Genetic Characteristics ◽  
New Developments ◽  
The Past

Over the past years, colorectal cancer (CRC) was subtyped according to its molecular and genetic characteristics, allowing the development of therapeutic strategies, based on predictive biomarkers. Biomarkers such as microsatellite instability (MSI), RAS and BRAF mutations, HER2 amplification or NTRK fusions represent major tools for personalized therapeutic strategies. Moreover, the routine implementation of molecular predictive tests provides new perspectives and challenges for the therapeutic management of CRC patients, such as liquid biopsies and the reintroduction of anti-EGFR monoclonal antibodies. In this review, we summarize the current landscape of targeted therapies for metastatic CRC patients, with a focus on new developments for EGFR blockade and emerging biomarkers (MSI, HER2, NTRK).

Sign in / Sign up

Export Citation Format

Share Document